Promethazine
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Promethazine — also known as Phenergan — is a synthetic antihistamine of the phenothiazine class. It shares its tricyclic scaffold with chlorpromazine but favors histamine blockade over dopamine antagonism. Promethazine is an H1 receptor inverse agonist, producing its effects by suppressing histamine-driven arousal and allergic signaling in the brain and periphery.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
diphenhydramine, chlorpheniramine, hydroxyzine +3 morediphenhydramine, chlorpheniramine, hydroxyzine, doxylamine, other first-generation H1 antihistamines, muscarinic antagonists show less
Synthesized in 1944 and identified as an antihistamine by Bernard Halpern at the CNRS in 1946, promethazine was approved by the US FDA in 1951.[2] Modifications to its phenothiazine scaffold led directly to chlorpromazine in 1952, making promethazine an ancestor of modern psychopharmacology. It remains widely prescribed for nausea, sedation, and allergic conditions, and has served as NASA's standard treatment for space motion sickness since 1989.[3]
Subjective effects include sedation, cognitive suppression, dry mouth, and visual acuity suppression. The experience is one of heavy, physically weighted drowsiness — thicker and more cognitively impairing than benzodiazepine sedation, with a distinctly anticholinergic character.[4] Constipation, orthostatic dizziness, and emotional suppression are characteristic unsought effects; at supratherapeutic doses, delirium with visual hallucinations emerges.[5]
Promethazine produces no established physical dependence, but carries two FDA black box warnings: fatal respiratory depression in children under 2 and severe tissue necrosis from injection.[6] Danger scales with combination use — promethazine potentiates opioid respiratory depression in codeine preparations, and its QT-prolonging potential compounds cardiac risk.[7][8] Seven decades of clinical use provide extensive safety data, though basic pharmacokinetic parameters remain uncharacterized in humans.
History[edit]
Discovery
Promethazine emerged from wartime phenothiazine chemistry. In 1944, Henry Gilman and David Stanley at Iowa State College synthesized the compound during investigations into phenothiazine derivatives as potential antimalarial agents.[2] Two years later, Bernard Halpern at the French National Centre for Scientific Research identified its antihistamine properties, and Rhône-Poulenc brought it to market in 1947. The US FDA approved promethazine for medical use in 1951.
Clinical and scientific significance
Promethazine's importance extends beyond its own clinical utility. Paul Charpentier's team at Rhône-Poulenc continued modifying the phenothiazine scaffold, producing chlorpromazine in 1952 — the first antipsychotic and the compound that launched modern psychopharmacology.[2] Promethazine itself became one of the most widely prescribed first-generation antihistamines, with indications spanning allergic conditions, nausea, motion sickness, and perioperative sedation under trade names including Phenergan, Lergigan, and Avomine.
Regulatory actions
In 2004, the FDA issued a black box warning contraindicating promethazine in children under 2 years after review of adverse event reports documented seven pediatric fatalities from respiratory depression.[6] A second black box warning addresses severe tissue injury from injection. In Denmark, promethazine was reclassified from over-the-counter to prescription-only in December 2014, following data showing it accounted for a disproportionate share of first-generation antihistamine poisonings.[9]
The name promethazine follows standard phenothiazine nomenclature, combining the propylamine side-chain designation with the "-azine" suffix denoting the thiazine ring system. Its best-known trade name, Phenergan, was introduced by Wyeth and remains the common reference in clinical and consumer contexts.
Chemistry[edit]
Structural class
Promethazine belongs to the phenothiazine chemical class — a tricyclic system comprising two benzene rings fused to a central thiazine ring. This scaffold is the parent structure for an entire family of neuroactive compounds, including the antipsychotics chlorpromazine, thioridazine, and fluphenazine. Promethazine is distinguished from the antipsychotic phenothiazines by its aliphatic (dimethylaminopropyl) side chain, which confers preferential antihistaminic over antidopaminergic activity.[2]
Molecular properties
| Molecular formula | C₁₇H₂₀N₂S |
| Molecular weight | 284.4 g/mol |
The molecule comprises a phenothiazine tricyclic core with a propylamine side chain bearing two methyl groups on the terminal nitrogen. The sulfur atom in the thiazine ring and the dimethylamino group contribute to the compound's lipophilicity and ability to cross the blood-brain barrier.[10]
Stereochemistry
Promethazine contains one chirality center and exists as a racemic mixture in all commercial formulations. The enantiomers display differential biological activity: the (+)-enantiomer produces greater suppression of inflammatory signaling than the (−)-enantiomer.[11] No enantiopure clinical formulation is currently available.
Stability
The free base is lipophilic; the hydrochloride salt used in pharmaceutical preparations is freely water-soluble. Solution stability is sensitive to light and temperature — at ambient conditions, only 38% of promethazine remained after 19 days in methanol, compared to 84% under refrigerated, dark storage.[12]
Pharmacology[edit]
Mechanism of action
Promethazine acts across multiple receptor systems simultaneously, producing a broad pharmacological profile.[13]
Its primary action is H1 histamine receptor inverse agonism. Promethazine blocks H1 receptors with exceptionally high affinity — stronger than most first-generation antihistamines — producing antiallergic, antipruritic, and sedative effects.[1]
Muscarinic receptor blockade is the second major axis. Promethazine is among the most potent antimuscarinic agents in the antihistamine class, driving dry mouth, constipation, urinary retention, rapid heart rate, dilated pupils, and cognitive impairment.[1][14]
Dopamine D2/D3 antagonism mediates the antiemetic effect at the brain's chemoreceptor trigger zone and can produce movement-related side effects at higher doses.[1][15] Additional blockade of serotonin 5-HT₂A/2C receptors contributes to sedation, and alpha-1 adrenergic antagonism produces blood pressure drops upon standing.[1]
The antiemetic effect involves a triple mechanism: dopamine blockade in the chemoreceptor trigger zone, histamine blockade in the vomiting center, and muscarinic blockade in the vestibular system.[15][13]
Pharmacokinetics
Oral bioavailability is low and highly variable at 12.3–40%, reflecting extensive first-pass liver metabolism.[16] Absorption varies dramatically between individuals and formulations — in one study of rectal suppositories, individual bioavailability ranged from 4% to 343%.[10]
Time to peak blood levels is slow: oral syrup reaches peak concentration at roughly 4.4 hours, rectal suppositories at 6.7–8.6 hours.[10] The half-life of 16–19 hours is notably long for a first-generation antihistamine, meaning residual effects persist well beyond the subjective peak.[10]
Promethazine is metabolized primarily through CYP2D6, which handles ring hydroxylation, sulfur oxidation, and demethylation.[17] Promethazine also inhibits CYP2D6, creating a pharmacokinetically paradoxical interaction with codeine: it blocks the enzyme that converts codeine to its active form (morphine), potentially reducing opioid potency while simultaneously adding to overall sedation.[18][17]
No published human data exist for plasma protein binding or volume of distribution — significant pharmacokinetic gaps for a drug prescribed since 1951.
Neuroscience[edit]
Where it acts
Promethazine's sedation originates from H1 receptor blockade in the tuberomammillary nucleus, the brain's primary histamine-driven wake center in the posterior hypothalamus.[13] The cognitive impairment — slowed responses, reduced accuracy — reflects muscarinic blockade in the hippocampus and basal forebrain, regions responsible for memory encoding and cortical arousal.[4]
Dopamine D2 blockade at the chemoreceptor trigger zone mediates antiemetic action. At supratherapeutic doses, widespread muscarinic disruption produces anticholinergic delirium: visual hallucinations, disorientation, and failed reality testing — pharmacologically analogous to the deliriant effects of diphenhydramine or scopolamine.[5]
Why it matters
The anticholinergic burden model provides the key clinical framework. Total muscarinic blockade from all concurrent medications determines cognitive impairment and delirium risk — promethazine's high muscarinic affinity makes it a major contributor to this cumulative burden, especially in elderly patients with reduced baseline cholinergic reserve.[19]
Under predictive processing theory, anticholinergic agents disrupt the brain's ability to weight sensory predictions against incoming data, producing the characteristic hallucinations and disorientation of delirium at high doses.
Several puzzles remain unresolved. NASA data show promethazine causes sedation in fewer than 5% of astronauts during spaceflight versus 60–73% on the ground[20] — the mechanism is unexplained. Given that CYP2D6 exclusively handles promethazine metabolism,[17] the impact of genetic poor-metabolizer status on drug exposure and adverse effects has never been studied in a genotyped cohort.
Subjective Effects[edit]
The promethazine experience is defined by heavy, physically weighted sedation accompanied by anticholinergic drying and cognitive fog. At therapeutic doses, the dominant quality is thick drowsiness with dry mouth, visual acuity suppression, and thought deceleration. As dose increases, the anticholinergic load intensifies — confusion and disorientation emerge, and at supratherapeutic levels the experience shifts into a deliriant state with visual hallucinations and impaired reality testing. Set and setting have minimal influence at clinical doses but become relevant in the delirium range, where environmental stimuli may be misinterpreted.
Compared to diphenhydramine, promethazine produces more intense sedation per milligram, reflecting its stronger receptor binding, and carries additional antidopaminergic effects absent in ethanolamine antihistamines. Relative to benzodiazepines, the sedation is less anxiolytic and more cognitively impairing, with a distinctly anticholinergic rather than GABAergic character.[4]
Effect Grid
Pronounced sedation dominates the experience — drowsiness is heavy and difficult to resist. Clear anticholinergic effects are present: dry mouth, blurred vision, constipation, and urinary hesitancy. Cognitive impairment is measurable, with reduced working memory accuracy and slowed information processing. Focus suppression and thought deceleration are prominent.
Physically, bodily heaviness is substantial and muscle relaxation is clear. Nausea suppression is reliable at this range. Mild tachycardia from muscarinic blockade may be noticeable. Dizziness on standing becomes more pronounced. Physical fatigue reinforces the sedation.
This is the standard therapeutic dose range for antiemesis and presurgical sedation. Functional impairment is significant — do not drive or operate machinery. Next-day residual drowsiness is expected from the long elimination half-life.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Visual haze / noise · Light sensitivity · Taste suppression · Tinnitus · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations
Tinnitus · Visual processing suppression · Auditory hallucinations · External hallucinations · Internal hallucinations
Dry mouth · Bodily heaviness · Dizziness · Pupil dilation · Muscle relaxation · Heart rate perception changes · Constipation · Appetite enhancement · Yawning · Pain suppression · Sexual arousal suppression · Restlessness · Nystagmus (eye wobbles) · Temperature dysregulation · Headache · Involuntary body movements · Muscle tension · Trembling · Bodily dissociation · Tactile hallucination
Pupil dilation · Muscle relaxation · Heart rate perception changes · Constipation · Appetite enhancement · Yawning · Pain suppression · Sexual arousal suppression · Restlessness · Nystagmus (eye wobbles) · Headache · Involuntary body movements · Muscle tension · Trembling · Bodily dissociation · Tactile hallucination
Cognitive fatigue · Analysis suppression · Information processing suppression · Motivation suppression · Memory suppression · Language suppression · Confusion · Memory fragmentation · Cognitive dysphoria · Thought disorganization · Delusions of sobriety · Amnesia · Delirium · Delusions
Motivation suppression · Memory suppression · Language suppression · Confusion · Memory fragmentation · Cognitive dysphoria · Thought disorganization · Amnesia · Delirium · Delusions
Anhedonia · Anxiety · Dysphoria · Irritability
Depersonalization · Derealization · Cognitive disconnection
Timeline
First awareness of drowsiness and slight dry mouth. The onset is gradual rather than abrupt — a slow thickening of fatigue rather than a discrete shift.
Sedation deepens progressively. Anticholinergic effects consolidate — dry mouth becomes definite, blurred vision may emerge. Cognitive slowing and bodily heaviness increase.
Maximum sedation with full anticholinergic burden. Cognitive impairment plateaus — working memory and reaction speed are measurably reduced. Nausea suppression is at its strongest.
Heavy sedation gradually lifts but residual drowsiness and dry mouth persist. Cognitive function begins recovering though remains below baseline. Motor coordination improves slowly.
Residual drowsiness and mild cognitive dulling from the 16–19 hour elimination half-life. Dry mouth may persist. Next-day hangover effect is common at therapeutic and supratherapeutic doses.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- diphenhydramine · chlorpheniramine · hydroxyzine
Toxicity
At recommended doses (12.5–50 mg oral), promethazine has a long safety record in adults since FDA approval in 1951.[13] Acute risk escalates sharply in three contexts.
Pediatric respiratory depression
Promethazine is contraindicated in children under 2 years. FDA review documented respiratory depression in 22 children aged 1.5 months to 2 years, with 7 fatalities, across all administration routes and a wide dose range (0.45–6.4 mg/kg).[6]
Injection-site tissue injury
Promethazine is a vesicant — caustic to blood vessels and surrounding tissue. Intravenous administration risks include blood vessel inflammation, accidental arterial injection, leakage into surrounding tissue, and tissue death.[13][21] Deep intramuscular injection is the only acceptable parenteral route.
Overdose
Overdose produces central nervous system depression and anticholinergic toxicity: dry mouth, urinary retention, rapid heart rate, overheating, dilated pupils, and delirium.[5] Skin absorption alone has produced full toxic syndromes including loss of coordination and visual hallucinations.[22] No specific antidote exists. No human lethal dose data have been established.
Heart and circulation
Promethazine is a recognized signal for dangerous heart rhythm disturbances (torsade de pointes) in pharmacovigilance data.[8] Risk increases with co-administered QT-prolonging drugs. In a study of 27,396 psychiatric hospital patients, replacing promethazine with alternatives was estimated to reduce QT-prolonging drug exposure by 11%.[23]
Blood pressure drops upon standing are common at standard doses.
Other organ effects
Promethazine causes light sensitivity and is used as a positive control in phototoxicity testing.[24] As a dopamine blocker, it can produce involuntary movements, muscle stiffness, and restlessness; chronic use carries risk of persistent movement disorders.[13]
Rare but serious effects include neuroleptic malignant syndrome (overheating, severe muscle rigidity, autonomic instability, and altered consciousness — potentially fatal) and bone marrow suppression.[13] Rare liver damage is a shared phenothiazine class effect.[13]
Laboratory interference
Promethazine produces false-positive urine amphetamine screening results, false-positive or false-negative pregnancy tests, and falsely elevated blood sugar test results.[13]
Psychological risks
Anticholinergic delirium is the primary psychological risk at supratherapeutic doses — confusion, disorientation, visual hallucinations (often shadow-like or indistinct figures), agitation, and impaired reality testing.[5] Unlike serotonergic psychedelic experiences, anticholinergic hallucinations are typically unpleasant, poorly recalled, and accompanied by cognitive impairment severe enough to preclude awareness of the altered state.
Paradoxical excitation — restlessness and hyperexcitability instead of sedation — is a recognized response, particularly in children.[13]
Cognitive impairment at clinical doses includes reduced working memory accuracy and slowed responses, particularly during physical movement or balance challenges.[4] The impairment exceeds that of meclizine and scopolamine and approaches benzodiazepine-level effects. Emotional blunting and dysphoria are reported at higher doses.
Tolerance and dependence
No published studies characterize tolerance development to promethazine's sedative or antiemetic effects specifically. First-generation H1 antihistamines as a class show reduced sedation with repeated use, but substance-specific data for promethazine are absent.[20]
Promethazine is not a controlled substance. No formal dependence assessment has been published. Misuse is documented in codeine combination products ("purple drank"), but the opioid component is primarily responsible for dependence in that formulation.[7] No published withdrawal data exist for promethazine discontinuation after chronic use.
Drug interactions
CNS depressant potentiation is the most significant interaction. FDA labeling mandates opioid dose reduction of 25–50% and barbiturate dose reduction of ≥50% when co-administered with promethazine.[13] Additive respiratory and central nervous system depression occurs with benzodiazepines, alcohol, and other sedatives. The promethazine–codeine combination in "purple drank" is the most prevalent recreational manifestation.[7]
CYP2D6 inhibition creates a paradoxical interaction with codeine: promethazine blocks the enzyme converting codeine to morphine, potentially reducing opioid potency while net sedation increases.[18][17] Other affected medications include tramadol, tricyclic antidepressants, tamoxifen, and some antipsychotics.
QT prolongation is additive with other QT-prolonging agents, significantly increasing heart rhythm risk.[8][23]
MAOIs increase the risk of involuntary movement side effects when combined with promethazine.[13]
Anticholinergic additivity with other muscarinic-blocking medications (tricyclics, antiparkinson agents, other first-generation antihistamines) compounds the risk of urinary retention, delirium, rapid heart rate, and cognitive impairment.[13]
Epinephrine is contraindicated for promethazine-induced low blood pressure — alpha-1 blockade can reverse the intended vasopressor effect, worsening the drop. Norepinephrine or phenylephrine should be used instead.[13]
Contraindications
Absolute:
- Children under 2 years — risk of fatal respiratory depression (FDA black box warning)[6]
- Arterial or subcutaneous injection — risk of tissue death; deep intramuscular is the only acceptable injection route[13]
- Comatose patients — worsens central nervous system depression[13]
- Known allergy to promethazine or other phenothiazines[13]
Relative:
- Concurrent MAOI use — increased risk of severe movement side effects[13]
- Lower respiratory tract disease — anticholinergic drying worsens airway conditions including asthma and COPD[13]
- Elderly patients — high anticholinergic burden increases risk of confusion, falls, and delirium; listed on the AGS Beers Criteria as potentially inappropriate[19]
- Liver impairment — impaired clearance may produce toxic buildup[13]
- Seizure disorders — phenothiazines may lower seizure threshold[13]
- Prostate enlargement or bladder obstruction — muscarinic blockade worsens urinary retention[13]
- Narrow-angle glaucoma — pupil dilation increases eye pressure[13]
- Concurrent QT-prolonging medications — additive heart rhythm risk[8]
Harm Reduction[edit]
Forms & Identification
Promethazine is available as tablets (12.5 mg, 25 mg, 50 mg), oral syrup, rectal suppositories, and injectable solution (intramuscular only). Pharmaceutical preparations are the standard source; diverted prescription medications and promethazine–codeine cough syrups are the primary forms encountered in recreational settings.
Absorption varies dramatically between formulations and individuals. Rectal suppositories show extreme unpredictability — absorption can range from negligible to several times the expected level in different people.[10] This variability makes dose-response prediction unreliable, particularly for non-oral routes.
Guidelines
- Start at the lowest effective dose. Individual response varies widely due to unpredictable absorption and metabolism.
- Do not combine with opioids, alcohol, benzodiazepines, or other sedatives without medical guidance — respiratory depression risk increases with each additional depressant.
- Allow at least 6 hours before driving or tasks requiring alertness, and assume residual impairment the following morning.
- Stand up slowly to avoid dizziness from blood pressure drops.
- Stay hydrated — anticholinergic drying affects the mouth, eyes, and urinary tract.
- Avoid direct sunlight exposure — promethazine causes light sensitivity.[24]
- If using rectal suppositories, be aware that absorption is extremely variable and do not re-dose based on delayed onset.
Set & Setting
The heavy sedation and cognitive impairment produced by promethazine make driving and operating machinery dangerous. The 16–19 hour half-life means residual impairment persists well beyond the period of felt drowsiness — next-morning effects should be assumed after evening doses.
An environment where the user can lie down safely is appropriate. Falls from sudden blood pressure drops on standing are a practical risk, especially when combined with other sedating substances.
Aftercare & integration. The extended half-life (16–19 hours) means residual drowsiness and cognitive dulling may persist into the following day. Plan for reduced performance on tasks requiring concentration or coordination.
Rehydrate and address anticholinergic side effects: drink water for dry mouth, use artificial tears for dry eyes if needed, and eat fiber-rich food to counter constipation. Resume normal sleep-wake patterns as soon as possible — promethazine can disrupt natural sleep architecture even as it induces sedation.
Recovery & Support
Promethazine itself is not typically associated with standalone dependence. Where problematic use occurs, it most commonly involves codeine combination products ("purple drank"), where the opioid component drives the dependence cycle.[7]
If promethazine use has become habitual for sleep or anxiety management, speak with a healthcare provider about tapering and alternative treatments. For codeine-promethazine combination dependence, opioid-specific treatment resources — including medication-assisted treatment programs — are the appropriate pathway.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Difficulty breathing, very slow or shallow breaths
- Unresponsiveness or inability to be woken
- Seizures
- Extreme confusion with overheating, severe muscle stiffness, and rapid heart rate (possible neuroleptic malignant syndrome)
- Chest pain or fainting (possible heart rhythm disturbance)
Immediate steps:
- Call emergency services immediately if the person is unresponsive, having difficulty breathing, or seizing.
- Place the person in the recovery position (on their side) if unconscious but breathing.
- Do not induce vomiting.
- Monitor breathing and heart rate while waiting for help.
- Keep the person cool if overheating.
What to tell the dispatcher: Name the substance (promethazine), estimated amount, time taken, and current symptoms. Mention any other substances involved, especially opioids or alcohol. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Important: If low blood pressure occurs, do not use epinephrine — it can worsen the drop due to promethazine's receptor blockade. Medical providers should use norepinephrine or phenylephrine instead.[13]
Legal Status[edit]
Promethazine is not classified as a controlled substance under international drug scheduling conventions or in most national frameworks. It is a prescription medication in most jurisdictions, with the notable exception of the United Kingdom where it is available over-the-counter.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Prescription only (Rx); not DEA-scheduled | FDA-approved since 1951. As of 2023, the 230th most commonly prescribed medication with over 1 million prescriptions annually. Two active black box warnings (pediatric respiratory depression; injection tissue injury)[13][2] |
| United Kingdom | Over-the-counter (OTC) | Available without prescription as Phenergan (10 mg, 25 mg tablets; 5 mg/5 mL elixir) for adults[25] |
| Canada | Non-prescription (some formulations) | Some formulations listed as non-prescription drugs. Codeine combinations may require prescription or pharmacist dispensing[25] |
| Australia | Schedule 4 (Prescription Only) | Regulated under the Therapeutic Goods Administration Poisons Standard. Codeine combinations are Schedule 4 or higher[25] |
| Denmark | Prescription only (since December 2014) | Reclassified from OTC following data showing disproportionate share of first-generation antihistamine poisonings, including intentional overdoses[9] |
| EU (general) | Varies by member state | Regulatory status differs across member states. Included on some national essential medicines lists for antiemetic and sedative usecitation needed |
references
- [1]
- [2]
- [3] ^Davis JR, Jennings RT, Beck BG (1993) Comparison of treatment strategies for Space Motion Sickness. — Acta astronautica PMID:11541638
- [4] ^abcdPaule MG, Chelonis JJ, Blake DJ, Dornhoffer JL (2004) Effects of drug countermeasures for space motion sickness on working memory in humans. — Neurotoxicology and teratology PMID:15451046
- [5] ^abcdPage CB, Duffull SB, Whyte IM, Isbister GK (2009) Promethazine overdose: clinical effects, predicting delirium and the effect of charcoal. — QJM : monthly journal of the Association of Physicians doi:10.1093/qjmed/hcn153
- [6]